Inari Medical, Inc. (NASDAQ: NARI) successfully completed the acquisition of LimFlow S.A., a leader in limb salvage for patients with chronic limb-threatening ischemia (CLTI). This strategic move aligns with Inari’s commitment to revolutionize treatment for venous and other diseases. Drew Hykes, CEO of Inari, expressed enthusiasm for integrating LimFlow’s groundbreaking technology, addressing a critical unmet need in vascular medicine. The $250 million upfront payment in cash, with potential additional payments of up to $165 million based on milestones, underscores Inari’s dedication to enhancing patient care and expanding its innovative portfolio.
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the close of its acquisition of LimFlow S.A., a privately-held pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI).
“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from CLTI,” said Drew Hykes, CEO of Inari. “LimFlow addresses one of the most significant unmet needs in all of vascular medicine, is closely aligned with our mission and adds another highly differentiated growth platform into our portfolio.”
On November 1, Inari announced a definitive agreement to acquire LimFlow, S.A. for a total upfront consideration of $250 million paid in cash upon closing. Contingent consideration of up to $165 million in additional cash payments are subject to the achievement of certain commercial and reimbursement milestones and will be paid out between 2025 and 2027. Inari funded the acquisition at close from existing cash resources.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace
